Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo
Either is defensible, but semaglutide carries the cardiovascular outcomes label, so it earns the first slot
People with cardiovascular risk Several GLP-1 drugs, including liraglutide, semaglutide, and dulaglutide, have demonstrated benefits in reducing the risk of heart attack, stroke, and cardiovascular death in people with Type 2 diabetes and existing heart disease
Its known for dark spots on the lips, inside the mouth, and sometimes on fingers and toes
This level of price decrease suggests semaglutide could ultimately retail for INR 5,000
Proper dosing starts at 2.5mg weekly, with gradual increases every four weeks until reaching the maximum dose of 15mg